HD-DXM promoted the expansion of MDSCs in patients with ITP. (A) Changes in the CD11b⁺CD33⁺HLA-DR^low cell population monitored before and after HD-DXM treatment (n = 21). (B) DXM with concentration gradients from 0.02 to 2 μM stimulated the expansion of MDSCs in a dose-dependent manner in 8 randomly selected patients in vitro. (C) Elevated percentages of CD11b⁺CD33⁺ cells after DXM (0.5 μM) modulation in vitro in cytokine-induced MDSCs from 16 patients with ITP. Differences between pre- and posttreatment groups were determined by paired Student t test. **P < .01.